Zealand Pharma A/S (ZLDPF.PK) announced on Monday promising topline results from its Phase 1b multiple ascending dose trial of dapiglutide, a long-acting dual agonist for GLP-1 and GLP-2 receptors, designed for the treatment of overweight and obesity.After 13 weeks, participants receiving dapiglutide achieved an average body weight reduction of up to 8.3% compared to the placebo group.The biotechnology firm is now assessing higher doses of dapiglutide, extending up to 26 mg, over a 28-week treatment period.Zealand Pharma intends to progress the clinical development of dapiglutide into a Phase 2b trial, projected to commence in the first half of 2025.As of now, Zealand Pharma’s stock is trading at $122.77, reflecting a decrease of 0.24% on the OTC Markets.The material has been provided by InstaForex Company – www.instaforex.com
- Oracle To Invest More Than $6.5 Bln In Malaysia For AI And Cloud Services - October 2, 2024
- Romania’s Producer Price Index Sees Slight Uptick in August 2024 - October 2, 2024
- Kenya’s GDP Growth Slows to 3.60% in Q2 2024 Amid Economic Headwinds - October 2, 2024
